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Introduction: This study assessed activity and safety of linifanib
(ABT-869), a selective inhibitor of vascular endothelial growth
factor and platelet-derived growth factor receptors, in patients with
locally advanced or metastatic non-small cell lung cancer.
Methods: In this open-label trial (NCT00517790), patients who
received one to two prior lines of systemic therapy were randomized
to oral linifanib 0.10 mg/kg (low dose) or 0.25 mg/kg (high dose)
once daily. Tumor responses were assessed by independent central
imaging review every 8 weeks. The primary end point was progres-
sion-free rate at 16 weeks. Secondary end points included objective
response rate, time to progression, progression-free survival, and
overall survival. Safety was also assessed.
Results: Between August 2007 and October 2008, 139 patients were
enrolled; 60% had two or more prior regimens, and 88% had
nonsquamous cell carcinoma. The objective response rate (low dose
and high dose) was 5.0% (3.1 and 6.8%), progression-free rate at 16
weeks was 33.1% (32.3 and 33.8%), median time to progression was
3.6 months (3.6 and 3.7 months), median progression-free survival
was 3.6 months (3.5 and 3.6 months), and median overall survival
was 9.0 months (10.0 and 8.3 months). The most common linifanib-
related adverse events were fatigue (42%), decreased appetite
(38%), hypertension (37%), diarrhea (32%), nausea (27%), palmar-
plantar erythrodysesthesia (24%), and proteinuria (22%). These
events were more common in the high-dose group. The most
common linifanib-related grade 3 or 4 adverse event was hyperten-
sion (14%).
Conclusions: Linifanib is active in advanced non-small cell lung
cancer as second- or third-line therapy. Increased adverse event rates
were observed at the high dose of linifanib.
Key Words: Angiogenesis, Linifanib (ABT-869), NSCLC, PDGFR,
VEGFR.
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Lung cancer has the highest incidence and mortality of anymalignancy worldwide, with an estimated 1.6 million new
cases and approximately 1.38 million deaths in 2008.1 The
most common type of lung cancer is non-small cell lung
cancer (NSCLC), comprising approximately 85% of all
cases.2,3 Despite recent advances in the management of ad-
vanced NSCLC, the highest 1-year survival rates range be-
tween 30 and 35%.4
Vascular endothelial growth factor (VEGF) is a key
mediator of angiogenesis in a variety of tumor types5,6 in-
cluding NSCLC. Blood vessels expressing VEGF are de-
tected in more than 50% of NSCLC tumor specimens, and the
degree of VEGF expression is predictive of metastatic dis-
semination and poor survival.2,5–7 Bevacizumab, a humanized
monoclonal antibody that binds selectively to VEGF, abro-
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gates ligand-induced activation of VEGF receptor (VEGFR).
In a phase 3 study (ECOG 4599), significant prolongation of
overall survival (OS) was observed in patients with bevaci-
zumab-eligible, advanced NSCLC. Patients in the first-line
setting were randomized to receive carboplatin plus paclitaxel
with placebo or bevacizumab.8 On the basis of these results,
bevacizumab was approved as first-line therapy in combina-
tion with carboplatin plus paclitaxel for the treatment of
patients with advanced NSCLC.2 In the randomized phase 3
AVAiL trial,9 patients with chemotherapy-naïve advanced or
recurrent NSCLC, who received bevacizumab plus cisplatin/
gemcitabine, had significant progression-free survival (PFS)
prolongation compared with those on placebo plus cisplatin/
gemcitabine, but significant OS benefit was not shown. These
results validated the targeting of VEGF-induced angiogenic
signaling as an effective therapeutic strategy for the treatment
of NSCLC. Platelet-derived growth factor (PDGF) also plays
an important role in tumor growth, and increased expression
has been associated with poor prognosis in NSCLC. To-
gether, VEGF and PDGF may enhance neoangiogenesis.6
Several multitargeted, small-molecule tyrosine kinase
inhibitors (TKIs) of the VEGF and other receptors are being
studied in phase 2 and 3 trials in advanced NSCLC.10,11
Although activity has been observed with these agents as
monotherapy or in combination with chemotherapy, efficacy
has not been established in phase 3 trials. Results of a phase
3 randomized, placebo-controlled trial with the multikinase
inhibitor, sorafenib, showed no clinical benefit of adding
sorafenib to carboplatin and paclitaxel as first-line treatment
for patients with NSCLC.10 Results from phase 3 trials of
vandetanib (VEGFR/EGFR TKI) in patients with previously
treated advanced NSCLC showed no clinical benefit versus
placebo, erlotinib, or in combination with pemetrexed,12–14
but did show a benefit in combination with docetaxel.15 Phase
3 trials in patients with advanced NSCLC of sorafenib as
monotherapy in the third/fourth-line setting versus placebo
and in combination with cisplatin and gemcitabine in the
first-line setting are ongoing.16,17 Phase 3 trials in patients
with advanced NSCLC with other multitargeted VEGFR
TKIs, including sunitinib, cediranib, motesanib, and BIBF-
1120, are also ongoing.18–22
Linifanib (ABT-869), a novel inhibitor that demon-
strates selectivity toward the VEGFR and PDGF receptor
(PDGFR) family of tyrosine kinases, has demonstrated potent
antiangiogenic and antitumor effects in preclinical stud-
ies.23–27 In a phase 1 study, linifanib as a single agent
demonstrated specific antitumor activity in 33 patients with
refractory solid malignancies. Of the 33 patients, 2 patients
with NSCLC and 1 with colorectal cancer achieved partial
responses (PRs), and several patients had prolonged stable
disease (SD). Dose-limiting toxicities were grade 3 hyperten-
sion, fatigue, and proteinuria.28 Continuous dosing of lini-
fanib at 0.25 mg/kg once daily was recommended for phase
2 studies.28 Nevertheless, because single-agent activity was
seen at 0.10 mg/kg, this dose was also evaluated. This phase
2 study was conducted to assess the efficacy and safety of
linifanib in patients with advanced NSCLC who experienced
disease progression after first- or second-line therapy.
PATIENTS AND METHODS
Patients
The study population consisted of patients who were
aged 18 years or older with histologically confirmed, locally
advanced or metastatic NSCLC, not amenable to cure; one or
more nonirradiated measurable lesion by computerized to-
mography scan as defined by RECIST29; Eastern Cooperative
Oncology Group performance status (ECOG PS) 0 to 2; and
adequate bone marrow, renal, and hepatic function. Patients
must have received one to two prior lines of systemic treat-
ment for advanced disease, including chemotherapy and tar-
geted therapies. Exclusion criteria included anticancer ther-
apy within 21 days or 5 half-lives before linifanib
administration; radiation therapy or major surgery within 21
days before linifanib administration; treatment with a
VEGFR, PDGFR tyrosine kinase-targeted agent (prior treat-
ment with EGFR-TKIs or bevacizumab was allowed); un-
treated brain or meningeal metastases; more than 10% weight
loss during the 6 weeks before study entry; significant central
thoracic lesions invading or abutting the heart or major blood
vessels with appreciable cavitation; hemoptysis (5 ml fresh
blood within 3 months before study entry); proteinuria more
than grade 1 severity of the National Cancer Institute Com-
mon Toxicity Criteria for Adverse Events version 3.030;
symptomatic or persistent, uncontrolled hypertension; left
ventricular ejection fraction less than 50%; and active therapy
for human immunodeficiency virus. All patients gave written,
informed consent before any screening procedures or study-
related procedures.
Study Design and Treatment
This study was a randomized, open-label, multina-
tional, multicenter phase 2 trial evaluating the efficacy of
low-dose (0.10 mg/kg) and high-dose (0.25 mg/kg) linifanib
in patients with advanced or metastatic NSCLC. Patients
were to be randomized in a 1:1 ratio to low-dose or high-dose
linifanib stratified by ethnicity. Oral linifanib was dosed once
daily under fasting conditions at bedtime. Treatment was to
continue until disease progression or intolerable toxicity.
Patients who experienced disease progression while receiving
low-dose linifanib could remain on study and cross over to
high-dose linifanib at the investigator’s discretion. Patients
were discontinued from the study if they exhibited disease
progression, drug-related toxicities that did not resolve to
grade 1 or baseline status within 14 days, or progressive
disease (PD). The protocol, amendments, and related docu-
ments were approved by independent ethics committees
and/or institutional review boards of the participating insti-
tutions. The study was conducted in accordance with the
International Conference on Harmonization guidelines, US
Food and Drug Administration regulations, all applicable
regulations, guidelines and laws governing clinical study
conduct, and the Declaration of Helsinki.
Assessments
All patients underwent screening evaluations and
baseline radiographic assessments within 21 days before
the first dose of linifanib. Baseline evaluations included
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physical examination, body weight, vital signs, ECOG PS
assessment, pregnancy test for female patients of child-
bearing potential, laboratory tests, and multiple-gated ac-
quisition scan/echocardiogram.
Additional radiographic tumor assessments were per-
formed every 8 weeks after initiation of linifanib using
computerized tomography scan of the full chest and abdo-
men.31,32 To assess tumor perfusion, dynamic contrast-en-
hanced magnetic resonance imaging scans were obtained on
day 1 before linifanib administration and 3 weeks after
initiation of linifanib therapy in selected patients.32 As this
was a multinational trial, all assessments of tumor lesions
were performed by an independent central imaging center
using radiographic images and according to RECIST.29 As-
sessment for clinical disease progression was evaluated by
the principal investigator during each patient visit. Survival
was assessed every 4 to 6 months after study discontinuation
for a period of less than or equal to 2 years. Data were
collected on case report forms by the investigator; the case
report forms were monitored and sent to the sponsor for
capture into the study database.
The primary efficacy end point was progression-free rate
(PFR) at week 16 based on clinical assessment by the investi-
gator and radiographic assessment by the central imaging center
according to RECIST.29 Secondary efficacy end points included
objective response rate (ORR), time to progression (TTP), PFS,
and OS. Safety assessments included the monitoring of labora-
tory test results and adverse events (AEs), which were graded
according to National Cancer Institute Common Toxicity Crite-
ria for Adverse Events version 3.0.30
Pharmacokinetics
Approximately 4 ml of blood sample was collected by
venipuncture into one potassium ethylenediaminetetraacetic acid
tube on weeks 2, 3, 4, 5, and end of week 8. These samples were
analyzed for plasma concentration of linifanib using LCMS/MS.
An analysis was performed using a nonlinear mixed-effect
population modeling approach with NONMEM software to
describe the disposition of linifanib at 0.10 and 0.25 mg/kg
doses and to identify significant covariates.
Statistical Analysis
Assuming the true PFR for the high-dose linifanib
group was 40% and the true PFR for the low-dose linifanib
group was 20%, with 57 patients per treatment group, this
study would have an 80% power at one-sided type 1 error rate
of 0.10. Enrollment of approximately 60 patients per dose
group was planned to offset the effect of dropouts from the
study. The SAS version 9.13 with UNIX operating system
was used to perform all statistical analyses. Statistical signif-
icance for all analyses was determined by a two-sided p value
less than or equal to 0.05, when rounded.
All randomized patients who received any linifanib
were included in the analysis of the primary efficacy end
point of PFR at week 16. The proportion of patients in each
dose group with PFR at week 16 and corresponding 95%
confidence intervals (CIs) were calculated using the binomial
distribution. The Fisher’s exact test was used to assess dif-
ferences in PFR between the two linifanib dose groups.
Analyses of secondary efficacy end points were per-
formed for all randomized and dosed patients in each dose
group. TTP, PFS, and OS were summarized using the Ka-
plan-Meier method.33 Median time to event and the corre-
TABLE 1. Patient and Disease Characteristics
All Patients
(N  139)
Linifanib Dose
0.10 mg/kg
(n  65)
0.25 mg/kg
(n  74)
Baseline Characteristics
Median age, yr 62 61 62
Male, n (%) 82 (59) 41 (63) 41 (55)
Asian, n (%) 49 (35) 23 (35) 26 (35)
ECOG PS, n (%)
0 45 (32) 23 (35) 22 (30)
1 88 (63) 38 (58) 50 (68)
2 6 (4) 4 (6) 2 (3)
Medical History at
Screening
Smoker (current and
ever), n (%)
Yes 95 (68) 41 (63) 54 (73)
No 44 (32) 24 (37) 20 (27)
Tumor histology, n (%)
Squamous 17 (12) 8 (12) 9 (12)
Nonsquamous 122 (88) 57 (88) 65 (88)
Prior systemic therapies,
n (%)
1 56 (40) 25 (39) 31 (42)
2 72 (52) 34 (52) 38 (51)
2 11 (8) 6 (9) 5 (7)
Prior bevacizumab
therapy, n (%)
25 (18.0) 12 (18.5) 13 (17.6)
ECOG PS, Eastern Cooperative Oncology Group performance status.
TABLE 2. Efficacy Results
End Points
All Patients
(N  139)
Linifanib Dose
0.10 mg/kg
(n  65)
0.25 mg/kg
(n  74)
Primary
PFRa at 16 wk, n (%) 46 (33.1) 21 (32.3) 25 (33.8)
95% CI 25.4–41.6 21.2–45.1 23.2–45.7
Secondary
Median PFS (mo) 3.6 3.5 3.6
95% CI 3.0–3.8 2.0–4.3 3.1–4.5
Median OS (mo) 9.0 10.0 8.3
95% CI 7.1–10.7 6.9–13.6 5.6–10.1
ORR,b n (%) 7 (5.0) 2 (3.1) 5 (6.8)
95% CI 2.0–10.1 0.4–10.7 2.2–15.1
Median TTP (mo) 3.6 3.6 3.7
95% CI 3.1–4.0 2.0–4.3 3.1–5.1
a PFR based on radiographic assessment by central imaging center and clinical
assessment by investigator.
b All responses were confirmed on two visits 4 wk apart.
PFR, progression-free rate; PFS, progression-free survival; OS, overall survival;
ORR, objective response rate; TTP, time to progression; CI, confidence interval.
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sponding 95% CI were presented for the overall patient
population and for each dose group. The distribution for TTP,
PFS, and OS was compared between the two linifanib dose
groups using the log-rank test statistics.
Safety was assessed by evaluating patient exposure to
study drug, AEs, serious AEs, deaths, and changes in labo-
ratory determinations and vital signs. Only treatment-emer-
gent AEs with onset on or after the first day of study drug and
less than or equal to 30 days after the last dose of drug were
included in the statistical analysis of safety. The number and
percentage of patients experiencing any treatment-emergent
AEs, AEs by toxicity grade, AEs by relationship to linifanib,
and AEs leading to drug discontinuation were summarized for
the total patient population and for each linifanib dose group.
The percentage of patients experiencing an AE was compared
between the two dose groups using Fisher’s exact test.
RESULTS
Patient Characteristics
From August 2007 to October 2008, 139 patients were
enrolled across 27 centers internationally. Sixty-five patients
were randomized to low-dose linifanib and 74 patients to
high-dose linifanib. Seven patients (11%) crossed over to
FIGURE 1. Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) in patients with advanced NSCLC.
A, PFS plot by dose group. B, OS plot by dose group. C, OS plot by Eastern Cooperative Oncology Group (ECOG) perfor-
mance status. CI, confidence interval; HR, hazards ratio.
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high-dose linifanib after experiencing disease progression at
the 0.10 mg/kg dose. The average initial fixed dose for 0.10
mg/kg was 6.6 mg (range 2.5–10.0 mg) and for 0.25 mg/kg
was 17.4 mg (range 7.5–25.0 mg).
Patient baseline and disease characteristics were well
balanced across linifanib dose groups (Table 1). The median
patient age was 62 years. Thirty-five percent of patients were
of Asian ethnicity. The majority of patients were male (59%),
current and ever smokers (68%), had tumors with nonsqua-
mous histology (88%), ECOG PS 1-2 (67%), and had re-
ceived two or more prior systemic therapies (60%; Table 1).
The median time from diagnosis to study start for all 139
patients was 14.4 months (range 10.9–23.6 months): 16.9
months (range 11.0–28.6 months) in the low-dose group and
13.6 months (range 10.4–22.0 months) in the high-dose group.
Best response to prior therapy for all 139 patients was 1 CR, 26
PR, 49 PD, and 50 SD (includes 3 unconfirmed PRs); best
response was unable to be determined for 13 patients.
Efficacy
The PFR at 16 weeks (95% CI) was 33.1% (25.4–
41.6), low dose 32.3% and high dose 33.8%, based on
radiographic assessment by the central imaging center and
clinical assessment by the investigator (Table 2). The median
PFS for the overall patient population was 3.6 months (range
3.0–3.8 months), and the median OS was 9.0 months (range
7.1–10.7 months; Table 2; Figure 1). The median TTP was
3.6 months (range 3.1–4.0 months; Table 2). Similar PFS and
TTP were observed in both dose groups. OS was 10 months
(range 6.9–13.6 months) for the low-dose group and 8.3
months (range 5.6 –10.1 months) for the high-dose group.
OS was significantly superior in patients with ECOG PS 0
compared with patients with ECOG PS 1 or 2 (Figure 1C).
The overall estimated ORR was 5.0% (range 2.0 –10.1%)
for low-dose and high-dose groups combined (Table 2,
Figure 2). Five patients treated with high-dose linifanib
achieved PR, none of whom had crossed over from low-
dose linifanib. In addition, 64 patients had both pre- and
post-treatment dynamic contrast-enhanced magnetic reso-
nance imaging scans. Of these, 25 (39%) had at least a
40% reduction in Ktrans consistent with an antiangiogenic
effect from linifanib.
Safety
Linifanib-related AEs reported by more than 20% of
patients included fatigue (41.7%), decreased appetite (38.1%),
FIGURE 1. Continued.
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hypertension (36.7%), diarrhea (31.7%), nausea (26.6%),
palmar-plantar erythrodysesthesia (23.7%), and proteinuria
(21.6%). The only linifanib-related grade 3 or 4 AEs ob-
served in more than 10% of patients was hypertension
(13.7%; Table 3). A higher rate of AEs was observed in
patients treated with high-dose linifanib compared with those
treated with low-dose linifanib (Table 3). Additional AEs
(independent of relationship to study drug) included rash (21
patients, 15.1%) and hypothyroidism (10 patients, 7.2%); 8
(5.8%) patients required thyroid hormone replacement ther-
apy. A higher rate of hypothyroidism was observed in the
high-dose linifanib treatment group. There was one fatal
event (pulmonary hemorrhage on day 62) that was considered
to be due to erosion of cancer into pulmonary blood vessels.
This patient had squamous histology and had been treated
with high-dose linifanib.
For 28.1% of patients, AEs led to dose reductions
(Table 3). A higher rate of dose reductions was observed in
patients treated with high-dose linifanib compared with pa-
tients in the low-dose group. The most common reasons for
dose reductions were proteinuria (11 patients, 7.9%), palmar-
plantar erythrodysesthesia (10 patients, 7.2%), and hyperten-
sion (8 patients, 5.8%). Dose interruption for hypertension
and proteinuria was mandated by the protocol. One hundred
twelve patients discontinued because of PD (clinical, radio-
graphic, or AE related to PD), 15 because of AEs not related
to PD, and 9 for other reasons; 3 remained on study, at the
time of the analysis.
Pharmacokinetics
Pharmacokinetic data were described by a one-compart-
ment model with first-order absorption and elimination. Cova-
riates such as body mass index, body surface area, body weight,
creatinine clearance, cancer type, formulation, race, and sex
were tested. The optimal model was defined as the model
containing only the most significant covariate relationships iden-
tified based on forward addition and backward elimination
process as evaluated by significant change in objective function
value. The model containing sex as a covariate on oral clearance
and body weight and sex as covariates on apparent volume of
distribution was identified as the optimal model. Estimates from
the optimal population pharmacokinetics model of effective
elimination half-life (t[1/2]) and oral clearance for the 0.10 mg/kg
group (n 51) and the 0.25 mg/kg group (n 70), respectively,
were t[1/2] (22.9 hours 9.2 and 20.5 hours 9.7, respectively)
and oral clearance (3.0 liter/h  1.2 and 3.7 liters/h  1.5,
respectively).
DISCUSSION
Anti-VEGF agents have proven efficacy in advanced
NSCLC when administered in combination with standard-of-
care chemotherapies. In two pivotal phase 3 trials (ECOG
FIGURE 2. Best percentage change from baseline in tumor size in patients with advanced non-small cell lung cancer treated
with linifanib. Pretreatment and posttreatment target lesions were assessed by central imaging using RECIST.
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4599 and AVAiL), the addition of bevacizumab, a monoclo-
nal VEGF antibody, to standard chemotherapy in advanced or
recurrent NSCLC resulted in clinically significant improve-
ment in PFS and/or OS.8,9,34 Small-molecule TKIs, which
target VEGF and other receptors, have shown activity as
monotherapy or in combination with chemotherapy in phase
2 trials, but have not provided evidence of efficacy in ran-
domized phase 3 trials in patients with advanced NSCLC.
Phase 3 investigation of several multitargeted VEGFR TKIs,
including sunitinib, cediranib, motesanib, and BIBF-1120, is
ongoing in this population.18–22
Linifanib is a potent and selective small-molecule in-
hibitor of the VEGFR and PDGFR families with minimal
activity against other protein kinases and strong antiangio-
genic and antitumor effects in preclinical models.24,35 In a
phase 1 study, confirmed PRs were observed with single-
agent linifanib in patients with metastatic NSCLC.28 The dose
levels in the present study were chosen based on results
from this phase 1 trial, which identified the recommended
phase 2 high dose at 0.25 mg/kg. As activity was also
observed at 0.10 mg/kg, this lower dose was also evaluated
in the current trial.
In this phase 2 trial, we evaluated the activity and safety
profile of linifanib as second- or later-line therapy in patients
with advanced NSCLC. The primary efficacy end point of
PFR at 16 weeks was 33.1% (low dose 32.3% and high dose
33.8%). The ORR was 5.0%; however, tumor size reduction
was observed in most of the patients. Although the response
rate by independent central imaging review was low, the
actual ORR per site assessments was 7.9% (low dose 4.6%
and high dose 10.8%). This is important to note as the
investigator assessments determined patient management and
continuation of linifanib. In addition, the proportion of pa-
tients with prolonged SD (PFS 3.6 months per central review)
is encouraging, particularly in a population in which 60% had
received two or more prior systemic therapies. The median
PFS and TTP were 3.6 months, and the median OS was 9.0
months. The median PFS from phase 2 trials of other TKIs
administered as monotherapy for NSCLC ranged from 2.2 to
4.9 months.36–40 There was no apparent dose relationship for
PFS or OS. Linifanib appeared to be more tolerable at the
lower dose but more active at the higher dose in terms of
response and degree of tumor size reduction. Although cau-
tion must be taken when making cross-study comparisons,
the median OS (9.0 months) in patients treated with single-
agent linifanib is comparable with that observed in a similar
population of patients with advanced NSCLC who received
second-/third-line therapy with erlotinib.36
AEs observed with linifanib included fatigue, hyperten-
sion, decreased appetite, diarrhea, nausea, proteinuria, and
palmar-plantar erythrodysesthesia. Of note, the AE profile
and the rate of AEs observed with linifanib were comparable
with that of other multitargeted, small-molecule VEGFR
TKIs administered as monotherapy for treatment of patients
with NSCLC.38,40–42 Fifteen patients withdrew from the
study because of linifanib-related toxicity (4 in the low-dose
group and 11 in the high-dose group). Despite allowing
patients with any histology into this study, only 17 patients
had squamous histology, and only 13 patients developed
hemoptysis (none were grade 3 or 4).
The pharmacokinetics of linifanib in this study are
similar between the 0.10 and 0.25 mg/kg dose groups. The
pharmacokinetics of linifanib in this study are also similar to
those of other patients with NSCLC from the linifanib phase
1 study and to those of patients with other tumor types from
linifanib phase 1/2 studies.
Linifanib is a highly selective inhibitor of VEGFR and
PDGFR with potent antiangiogenic and anticancer properties.
On the basis of the clinical activity and acceptable safety profile
of single-agent linifanib demonstrated in this study, further
evaluation of linifanib in patients with advanced NSCLC should
be considered as combination therapy. A randomized phase 2
trial of carboplatin/paclitaxel in combination with linifanib at
lower doses (7.5 or 12.5 mg) or placebo is ongoing.43
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TABLE 3. Linifanib-Related Adverse Events and Dose
Reductions Due to Linifanib-Related Adverse Events
All
Patients,
n (%)
(N  139)
Linifanib Dose,
n (%)
pa
0.10
mg/kg
(n  65)
0.25
mg/kg
(n  74)
AEs, Any Grade
(>20% of all
patients)
Fatigue 58 (41.7) 21 (32.3) 37 (50.0) 0.040b
Decreased appetite 53 (38.1) 18 (27.7) 35 (47.3) 0.023b
Hypertension 51 (36.7) 15 (23.1) 36 (48.6) 0.003b
Diarrhea 44 (31.7) 15 (23.1) 29 (39.2) 0.046b
Nausea 37 (26.6) 14 (21.5) 23 (31.1) —c
Palmar-plantar
erythrodysesthesia
33 (23.7) 12 (18.5) 21 (28.4) —c
Proteinuria 30 (21.6) 5 (7.7) 25 (33.8) 0.001b
AEs, Grade 3 or 4
(>10% of all
patients)
Hypertension 19 (13.7) 1 (1.5) 18 (24.3) 0.001b
Dose Reduction
Due to AEs 39 (28.1) 7 (10.8) 32 (43.2) 0.001b
Most common reasons
Proteinuria 11 (7.9) 3 (4.6) 8 (10.8) —c
Hypertension 8 (5.8) 0 8 (10.8) 0.007b
Palmar-plantar
erythrodysesthesia
10 (7.2) 3 (4.6) 7 (9.5) —c
a p value for comparison between 0.25 mg/kg versus 0.10 mg/kg treatment groups
using Fisher’s exact test.
b Statistically significant difference between groups.
c No statistical difference.
AE, adverse event.
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